Prospective Grant of Exclusive License: Development and Use of Cripto-1 as a Biomarker and Treatment for Neurodegenerative Disease, 45407 [05-15540]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 150 / Friday, August 5, 2005 / Notices
ACTION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Targeting
Technologies.
Date: August 5, 2005.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Steven J. Jullo, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4192,
MSC 7849, Bethesda, MD 20892, (301) 435–
2810, zullost@scr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 1, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–15538 Filed 8–4–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Development and Use of
Cripto-1 as a Biomarker and Treatment
for Neurodegenerative Disease
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
VerDate jul<14>2003
15:34 Aug 04, 2005
Jkt 205001
Notice.
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in U.S. Patent Application
60/508,750, filed October 3, 2003
[DHHS Ref. E–075–2003/0–US–01] and
PCT Application PCT/US04/32649
[DHHS Ref. E–075–2003/0–PCT–02],
entitled Use of Cripto-1 as a Biomarker
for Neurodegenerative Disease and
Method of Inhibiting Progression
Thereof, to Neuronascent, Inc., which is
located in Clarksville, Maryland. The
patent rights in these inventions have
been assigned to the United States of
America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the
development and use of Cripto small
molecule inhibitors to treat and prevent
Alzheimer’s disease in humans.
DATES: Only written comments and/or
applications for a license, which are
received by the NIH Office of
Technology Transfer on or before
October 4, 2005 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: Michelle A. Booden,
Ph.D., Technology Licensing Specialist,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; telephone: (301) 451–7337;
Facsimile: (301) 402–0220; e-mail:
boodenm@mail.nih.gov.
The
technology relates to another use of
Cripto-1 as a biomarker and possible
therapeutic target for a variety of
neurodegenerative diseases, including
NeuroAids, Alzheimer’s disease,
Multiple Sclerosis, Amyotrophic Lateral
Sclerosis, Parkinson’s disease and
encephalitis. Cripto-1 appears to be
overexpressed by 20-fold or more in
NeuroAids and as such, may be
enhanced in other inflammatory
neurological diseases, and thus assist in
the early detection of neurological
changes associated with these diseases,
as well as a possible therapeutic target
for slowing progression.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within sixty (60) days from the date of
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
45407
this published notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: July 28, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–15540 Filed 8–4–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer on (240) 276–
1243.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
E:\FR\FM\05AUN1.SGM
05AUN1
]]>Agencies
[Federal Register Volume 70, Number 150 (Friday, August 5, 2005)]
[Notices]
[Page 45407]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-15540]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Development and Use of
Cripto-1 as a Biomarker and Treatment for Neurodegenerative Disease
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department
of Health and Human Services, is contemplating the grant of an
exclusive patent license to practice the inventions embodied in U.S.
Patent Application 60/508,750, filed October 3, 2003 [DHHS Ref. E-075-
2003/0-US-01] and PCT Application PCT/US04/32649 [DHHS Ref. E-075-2003/
0-PCT-02], entitled Use of Cripto-1 as a Biomarker for
Neurodegenerative Disease and Method of Inhibiting Progression Thereof,
to Neuronascent, Inc., which is located in Clarksville, Maryland. The
patent rights in these inventions have been assigned to the United
States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the development and use of Cripto
small molecule inhibitors to treat and prevent Alzheimer's disease in
humans.
DATES: Only written comments and/or applications for a license, which
are received by the NIH Office of Technology Transfer on or before
October 4, 2005 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
license should be directed to: Michelle A. Booden, Ph.D., Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; telephone: (301) 451-7337; Facsimile: (301) 402-0220; e-
mail: boodenm@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The technology relates to another use of
Cripto-1 as a biomarker and possible therapeutic target for a variety
of neurodegenerative diseases, including NeuroAids, Alzheimer's
disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Parkinson's
disease and encephalitis. Cripto-1 appears to be overexpressed by 20-
fold or more in NeuroAids and as such, may be enhanced in other
inflammatory neurological diseases, and thus assist in the early
detection of neurological changes associated with these diseases, as
well as a possible therapeutic target for slowing progression.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless within sixty
(60) days from the date of this published notice, the NIH receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: July 28, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 05-15540 Filed 8-4-05; 8:45 am]
BILLING CODE 4140-01-P
